Weight-Loss Drugs for Children as Young as Six Warrant Consideration, Columnist Argues

A recent analysis of weight-loss trials involving overweight children suggests that medications such as semaglutide, known commercially as Ozempic and Wegovy, could be beneficial for individuals as young as six. The study, led by the University of Western Ontario in Canada, examined 756 children aged six to 17, finding that participants lost an average of 11 pounds (5 kg). Those treated with semaglutide shed an average of nearly 18 kg, according to one of the academics involved, Dr. Manpreet Kaur Oberoi.

Dr. Oberoi stated that the medicines were "significantly efficient in lowering the BMI, weight, heart rate and systolic blood pressure and in improving quality of life, while maintaining a manageable safety profile." The findings propose that if the benefits outweigh the risks, these medications should be considered for children experiencing the physical and mental health challenges associated with obesity.

This perspective comes as childhood obesity is described as a national crisis, with 22% of children obese and another 13% overweight by their final year of primary school. It is estimated that 80% of obese adolescents go on to become obese adults, facing a higher risk of heart disease, stroke, Type 2 diabetes, cancer, joint issues, and low self-esteem.

The argument for considering weight-loss injections for young children is made in the context of a society where children are constantly exposed to high-calorie temptations, making it difficult for parents to manage their diets. Factors such as the decline of outdoor play, closure of youth clubs, increased screen time, and the pervasive availability of ultra-processed foods contribute to this challenge.

While acknowledging the discomfort many may feel about medicating young children, proponents argue that for those significantly affected by obesity, such interventions could be life-changing. The column suggests that educational campaigns alone have proven insufficient against the omnipresence of cheap and accessible ultra-processed foods, necessitating alternative strategies.

This discussion highlights the complex interplay between parental responsibility, societal influences, and the evolving landscape of medical interventions for pediatric health concerns. The debate around the use of these powerful drugs in children is expected to continue as rates of childhood obesity remain a significant public health issue.